KOMBINASI AMLODIPIN MICARDIS; STUDI PERSPEKTIF EFEKTIVITAS BIAYA PENGOBATAN HIPERTENSI
Abstract
Biaya untuk mengobati hipertensi secara efektif sangat besar. Maka dari itu kajian farmakoekonomi penting untuk dilakukan. Penelitian ini bertujuan untuk mendapatkan perbandingan efektivitas biaya antara penggunaan amlodipin, micardis dan kombinasi amlodipin micardis pada pasien hipertensi di instalasi rawat jalan RSUP dr.Wahidin Sudirohusodo Makassar periode tanggal 1 April sampai dengan 31 Mei 2019. Penelitian ini merupakan penelitian observasional analitik dengan rancangan kohort retrospektif yang pengambilan sampelnya dilakukan dengan teknik purposive sampling. Dari hasil penelitian diperoleh 30 sampel yaitu 10 yang menggunakan amlodipin, 9 menggunakan micardis dan 11 menggunakan kombinasi amlodipin micardis. Penggunaan kombinasi amlodipin micardis memiliki efektivitas biaya lebih baik dibandingkan penggunaan amlodipin dan micardis dalam menurunkan tekanan darah sistolik sedangkan dalam menurunkan tekanan darah diastolik penggunaan amlodipin memiliki efektivitas biaya lebih baik dibandingkan penggunaan micardis dan kombinasi amlodipin micardis. Efek samping paling dominan muncul pada penggunaan amlodipin secara monoterapi, yaitu edema. Maka disimpulkan bahwa penggunaan kombinasi terapi antara amlodipin dan micardis memiliki efektivitas biaya lebih baik dibandingkan penggunaan secara monoterapi dalam menurunkan tekanan darah dan mengurangi terjadinya efek samping.References
Billecke, SS and Marcovitz PA. 2013. Long-term Safety and Efficacy of Telmisartan/Amlodipin singke Pill Combination in the Treatment of Hypertension. Vascular Health and Risk Management. 2013 : 9. 95-104.
Badan Penelitian dan Pengembangan Kesehatan. 2013. Riset Kesehatan Dasar Riskesdas 2013. Jakarta : Kementerian Kesehatan RI.
Badan Penelitian dan Pengembangan Kesehatan. 2018. Riset Kesehatan Dasar Riskesdas 2018. Jakarta : Kementerian Kesehatan RI.
Badan Pusat Statistik Sulawesi Selatan. 2015. Jumlah Kasus Sepuluh Penyakit Terbanyak di Provinsi Sulawesi Selatan. Makassar : Dinas Kesehatan Provinsi Sulawesi Selatan.
Chobaniam AV et al. 2003. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA ;289:2560-2572.
Dipiro, et al. 2005. Pharmacotherapy: A Pathophysiologic Approach, 6th ed. United State of America : Mc Graw – Hill.
Dipiro, et al. 2011. Pharmacotherapy: A Pathophysiologic Approach, 8th ed. United State of America : Mc Graw – Hill.
Gattani, G. S. Patil, B. Abasehab, Kushare, S. Sachin. 2009. Pharmacoeconomic Review. 2(3): 15-26.
Goyal J, et al. 2014. Comparative Study of High Dose Monotherapy of Amlodipine or Telmisartan, and Their Low Dose Combination in Mild to Moderate Hypertension. Journal of Clinical and Diagnostic Research. Vol-8(6):HC08-HC11.
Kementrian Kesehatan Republik Indonesia. 2013. Pedoman Penerapan Kajian Farmakoekonomi. Jakarta : Direktorat Jendral Bina Kefarmasian dan Alat Kesehatan.
Miura S and Saku S. 2012. Efficacy and Safety of Angiotensin II Type 1 Receptor Blocker/Calcium Channel Blocker Combination Therapy for Hypertension: Focus on a Single-pill Fixed-dose Combination of Valsartan and Amlodipine. The Journal of International Medical Research. 2012; 40: 1 – 9.
Park, et al. 2017. Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review. American Journal of Preventive Medicine. 53(6S2):S131-S142.
Philipp T, Smith TR, Glazer R, et al: Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007; 29: 563 – 580.
Rascati, K.L., et al, 2009, Essentials of Pharmacoeconomics, Lippincott Williams & Wilkies, Philadelphia.
Reeder, C. E. 1995. Overview of Pharmacoeconomics and Pharmaceutical Outcomes Evaluations. American Journal of Health-System Pharmacy, ASHP, 330(3): 679-686.
Saito, I, et al. 2008. Cost-Utility Analysis of Antihypertensive Combination Therapy in Japan by a Monte Carlo Simulation Model. Hypertens Res. Vol. 31. No. 7. 1373 – 1383.
Wu Y, et al. 2013. A Cost Effectiveness Analysis between Amlodipine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention among Hypertension Patients in China. Value in Health Regional Issues. 2 (2013) 75-80.
Downloads
Published
Issue
Section
License
The copyright to this article is transferred to Universitas Hasanuddin (UNHAS) if and when the article is accepted for publication. The undersigned hereby transfers all rights in and to the paper including without limitation all copyrights to UNHAS. The undersigned hereby represents and warrants that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required. The undersigned represents that he/she has the power and authority to make and execute this assignment.
We declare that:
- This paper has not been published in the same form elsewhere.
- It will not be submitted anywhere else for publication prior to acceptance/rejection by this Journal.
- A copyright permission is obtained for materials published elsewhere and which require this permission for reproduction.
Furthermore, I/We hereby transfer the unlimited rights of publication of the above-mentioned paper in whole to UNHAS The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, microform, electronic form (offline, online) or any other reproductions of similar nature.
The corresponding author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. This agreement is to be signed by at least one of the authors who have obtained the assent of the co-author(s) where applicable. After submission of this agreement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted.
